by offering coaching and connected devices to help more than 800,000 patients manage their diabetes and other chronic conditions. Now, as the rise of these powerful drugs upends the weight-loss industry, Omada is grappling with how it can play a role.
"Omada's gonna do pretty much the exact opposite of what we're seeing in the digital-health landscape in our competitive set and actually not write GLP scripts," CEO Sean Duffy told Insider in an interview. But here's where Omada is making a big gamble: It wants to help people stop taking the drugs after a period of time. The goal is that by changing their habits, Omada can help patients keep a lot of the weight off, even though clinical-trial dataThe program will launch with a large employer in July, Duffy said.